 |
0 Products |  |
0 Diseases | | 0 Products |
|
0 Trials |  |
1 News |  |
| «12 |
- || inobrodib (CCS1477) / CellCentric
Trial primary completion date, Monotherapy, Metastases: CCS1477-02: Study to Evaluate CCS1477 in Haematological Malignancies (clinicaltrials.gov) - Aug 18, 2021
P1/2, N=90, Recruiting, Sponsor: CellCentric Ltd.
Trial primary completion date: Dec 2020 --> Dec 2021
- CCS1477 / CellCentric
[VIRTUAL] A phase I/IIa study to evaluate the safety and efficacy of CCS1477, a first in clinic inhibitor of p300/CBP, as monotherapy in patients with selected molecular alterations () - Aug 15, 2021 - Abstract #ESMO2021ESMO_3288;
P1/2
Anti-tumour activity will be determined by standard imaging according to RECIST guidelines. Paired tumour biopsies for biomarker assessment are being collected.
- || inobrodib (CCS1477) / CellCentric
Trial primary completion date, Monotherapy: Study to Evaluate CCS1477 in Advanced Tumours (clinicaltrials.gov) - Jul 12, 2021
P1/2, N=200, Recruiting, Sponsor: CellCentric Ltd.
Paired tumour biopsies for biomarker assessment are being collected. Trial primary completion date: Mar 2021 --> Dec 2021
- || CCS1477 / CellCentric
Review, Journal: Current development of CBP/p300 inhibitors in the last decade. (Pubmed Central) - Apr 21, 2021
In particular, the CBP/p300 bromodomain inhibitor CCS1477, identified by CellCentric, is currently undergone clinical evaluation for the treatment of haematological malignancies and prostate cancer. In this review, we depict the development of CBP/p300 inhibitors reported from 2010 to 2020 and particularly highlight their structure-activity relationships (SARs), binding modes, selectivity and pharmacological functions with the aim to facilitate rational design and development of CBP/p300 inhibitors.
- |||| CCS1477 / CellCentric
Clinical, PK/PD data: #PYC #Physiomics @Physiomics Project agreement on #CCS1477 The project will involve PK/PD modelling and build on the work completed over the course of 2019 in support of the clinical development of CellCentric's lead asset CCS1477. (Twitter) - Apr 2, 2021
- ||||| CCS1477 / CellCentric
Great to see CellCentric’s CCS1477 profiled, first-in-class p300/CBP inhibitor. Collaboration with colleagues ICR/Royal Marsden. @neerajaiims @OncoAlert @CellCentric https://t.co/7NbI5HOEAj (Twitter) - Apr 1, 2021
- CCS1477 / CellCentric
[VIRTUAL] Linking Metabolism to Epigenetic Dysfunction in Pulmonary Arterial Hypertension: Role for the ACLY/P300 Axis () - Mar 14, 2021 - Abstract #ATS2021ATS_3023;
We show that ACLY-P300 axis contributes to both metabolic and epigenetic dysregulation observed in PAH, leading to pulmonary vascular remodeling and RV dysfunction. Their inhibition may represent a new therapeutic avenue.
- || inobrodib (CCS1477) / CellCentric
Trial primary completion date, Monotherapy: Study to Evaluate CCS1477 in Advanced Tumours (clinicaltrials.gov) - Jan 26, 2021
P1/2, N=200, Recruiting, Sponsor: CellCentric Ltd.
Their inhibition may represent a new therapeutic avenue. Trial primary completion date: Dec 2020 --> Mar 2021
- ||||| CCS1477 / CellCentric
Clinical: #PYC from the @ICR_London notes. This is where IMHO JM should be mentioning @Physiomics at every opportunity here: The ICR article mentions @CellCentric (obviously) @SKCCDirector & @TJUHospital We know #PYC are intrinsically linked to #CCS1477 ICR could have mentioned them?? (Twitter) - Jan 14, 2021
- |||| CCS1477 / CellCentric
P1 data: Major breakthrough! Fantastic achievement from Cell Centric in collaboration with De Bono & Knudsen groups. CCS1477 Early Phase I looks promising. Looking forward to US/other sites opportunities!! @jodebon @SKCCDirector @Nb10Nigel @AdamSharpMedOnc @PCF_Science #prostatecancer (Twitter) - Jan 12, 2021
- ||| inobrodib (CCS1477) / CellCentric
Enrollment change, Monotherapy: Study to Evaluate CCS1477 in Advanced Tumours (clinicaltrials.gov) - Nov 23, 2020
P1/2, N=200, Recruiting, Sponsor: CellCentric Ltd.
Trial primary completion date: Dec 2020 --> Mar 2021 N=120 --> 200
- EP-300 / Esperance Pharma
[VIRTUAL] The Epigenetic Modifier EP300: A New Corner Stone in the Regulation of Both Vascular Remodeling and Right Ventricle Failure in Pulmonary Arterial Hypertension (OnDemand) - Sep 22, 2020 - Abstract #AHA2020AHA_4577;
N=120 --> 200 EP300 upregulation contributes to both pulmonary vascular remodeling and RV dysfunction seen in PAH and its inhibition represents a promising therapeutic avenue.
- || inobrodib (CCS1477) / CellCentric
Trial primary completion date, Monotherapy: Study to Evaluate CCS1477 in Advanced Tumours (clinicaltrials.gov) - Mar 3, 2020
P1/2, N=120, Recruiting, Sponsor: CellCentric Ltd.
EP300 upregulation contributes to both pulmonary vascular remodeling and RV dysfunction seen in PAH and its inhibition represents a promising therapeutic avenue. Trial primary completion date: Jan 2020 --> Dec 2020
- ||| CCS1477 / CellCentric
Clinical: New guy at @CellCentric been at @IQVIA_global & @Roche and also @PharmOlam https://t.co/OgxsoiLxAL #PYC #CCS1477 (Twitter) - Feb 3, 2020
- ||||| CCS1477 / CellCentric
CellCentric at ASH next week. CCS1477 p300/CBP inhibitor in trials to treat multiple myeloma and other haem malignancies. #ASH19 (Twitter) - Nov 27, 2019
- ||| CCS1477 / CellCentric
Great to be back in Philly. Collaboration with @SKCCDirector TJU, now looking forward to seeing CCS1477 in the clinic in the US. (Twitter) - Nov 15, 2019
- azacitidine / Generic mfg., CCS1477 / CellCentric
CCS1477: A Novel Small Molecule Inhibitor of p300/CBP Bromodomain for the Treatment of Acute Myeloid Leukaemia and Multiple Myeloma (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_3729;
These data support the clinical testing of CCS1477 in haematological malignancies, including MM and AML, with a strong pre-clinical rationale for use as monotherapy or in combination with standard of care agents, such as lenalidomide. CCS1477 is currently in Phase I/II clinical trials.
- CCS1477 / CellCentric
An Open-Label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477, a First in Clinic Inhibitor of the p300/CPB Bromodomains, As Monotherapy in Patients with Advanced Haematological Malignancies (Hall B, Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_2085;
This will include the analysis of tumour-specific and circulating biomarkers, such as tumour DNA, mRNA, proteins or metabolites . In NHL patients, analysis of CBP (and p300) mutations will be undertaken to allow retrospective correlation with tumour response and to determine if loss of function mutations in the genes for either proteins can be utilised as response predictive biomarkers in future studies.
- | inobrodib (CCS1477) / CellCentric
New P1/2 trial, Monotherapy, Metastases: CCS1477-02: Study to Evaluate CCS1477 in Haematological Malignancies (clinicaltrials.gov) - Aug 28, 2019
P1/2, N=90, Recruiting, Sponsor: CellCentric Ltd.
- ||||| CCS1477 / CellCentric
CellCentric in Chicago, end of May for #ASCO19. CCS1477, our first-in-class p300/CBP inhibitor, in the clinic. (Twitter) - May 8, 2019
- | inobrodib (CCS1477) / CellCentric
Enrollment open, Monotherapy: Study to Evaluate CCS1477 in Advanced Tumours (clinicaltrials.gov) - Jul 3, 2018
P1/2, N=120, Recruiting, Sponsor: CellCentric Ltd.
In NHL patients, analysis of CBP (and p300) mutations will be undertaken to allow retrospective correlation with tumour response and to determine if loss of function mutations in the genes for either proteins can be utilised as response predictive biomarkers in future studies. Not yet recruiting --> Recruiting
- | inobrodib (CCS1477) / CellCentric
New P1/2 trial, Monotherapy: Study to Evaluate CCS1477 in Advanced Tumours (clinicaltrials.gov) - Jun 26, 2018
P1/2, N=120, Not yet recruiting, Sponsor: CellCentric Ltd.